MedTrace Logo

Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

NCT03866707 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2023-12-20

No results posted yet for this study

Summary

The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.

Conditions

  • Childhood Cancer

Interventions

OTHER

One-time blood draw

Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size. Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing. Metabolomic analysis will be performed by mass spectrometry when funds are available.

OTHER

Evaluation of CpG methylation

Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.

OTHER

Metabolomic analysis

Metabolomic analysis will be performed by mass spectrometry when funds are available.

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Kevin Buckley, MD · Wake Forest University Health Sciences

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2020-05-16
Completion
2020-05-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03866707 on ClinicalTrials.gov